Interleukin 9 (IL9) (AA 19-144) (Active) Protein

Details for Product No. ABIN2666534, Supplier: Log in to see
Protein Name
  • IL9
  • IL-9
  • Il-9
  • P40
  • HP40
  • interleukin 9
  • interleukin 9-like
  • IL9
  • il9
  • Il9
  • LOC100340820
Protein Characteristics
AA 19-144
12
2
2
1
Origin
Mouse (Murine)
42
19
4
Source
Insect Cells
39
8
3
2
2
1
1
1
Protein Type
Recombinant
Biological Activity
Active
Application
Flow Cytometry (FACS)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Purity > 95 % , as determined by Coomassie stained SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level

Less than 0.1 EU per μg of protein as determine by the LAL method.

Background IL-9 was initially identified in mice as a T cell growth factor. Human and murine IL-9 show 56 % amino acid sequence homology. IL-9 is a cytokine that acts as a regulator of a variety of hematopoietic cells, stimulates cell proliferation, and prevents apoptosis. The IL-9 receptor consists of the cytokine-specific IL-9 receptor α-chain (IL-9Rα) and the common γ-chain that is shared by IL-2, IL-4, IL-7, IL-15 and IL-21. IL-9 is expressed by activated Th9, Th17, Treg, and mast cells and appears to play important roles in the development and function of subsets within the CD4+ T cell lineage. IL-9 also inhibits immune responses by enhancing the suppressive properties of Tregs and by recruiting immune suppressive mast cells to sites of inflammation. Genetic studies on a mouse model of asthma demonstrated that this cytokine is a key factor in the pathogenesis of bronchial hyperresponsiveness. In this sense, it has been described that IL-9 and IL-9R expression are increased in lungs of asthmatic patients. In addition, IL-9 promotes mast cell mediated intestinal permeability and plays a role in the development of food allergies. Also, IL-9 has been associated with atopic dermatitis.
Molecular Weight The 125 amino acid recombinant protein has a predicted molecular mass of approximately 14 kDa. The DTT-reduced protein migrate as multiple bands between 17-25 kDa by SDS-PAGE due to different glycosylation. The predicted N-terminal amino acid is Gln.
Research Area Cytokines, Immunology, Virology, Inflammation, Cancer
Pathways JAK-STAT Signaling
Application Notes Optimal working dilution should be determined by the investigator.
Comment

Biological activity: Mouse IL-9 induces proliferation of MO7e cells. The ED50 is 0.04 - 0.16 ng/ml, corresponding to a specific activity of 6.5 - 25.0 x 106 units/mg.

Restrictions For Research Use only
Format Liquid
Reconstitution For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.
Buffer 0.22 μm filtered protein solution is in PBS.
Handling Advice Avoid repeated freeze/thaw cycles.
Storage -20 °C
Storage Comment Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.
Supplier Images
ELISA image for Interleukin 9 (IL9) (AA 19-144) (Active) Protein (ABIN2666534) Interleukin 9 (IL9) (AA 19-144) (Active) protein
Background publications Sismanopoulos, Delivanis, Alysandratos, Angelidou, Vasiadi, Therianou, Theoharides: "IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis." in: PLoS ONE, Vol. 7, Issue 3, pp. e33271, 2012 (PubMed).

Goswami, Kaplan: "A brief history of IL-9." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 186, Issue 6, pp. 3283-8, 2011 (PubMed).

Tan, Aziz, Lovaas, Vistica, Shi, Wawrousek, Gery: "Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 185, Issue 11, pp. 6795-801, 2010 (PubMed).

Kaiko, Foster: "New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma." in: Current opinion in allergy and clinical immunology, Vol. 11, Issue 1, pp. 39-45, 2010 (PubMed).

Jäger, Dardalhon, Sobel, Bettelli, Kuchroo: "Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 183, Issue 11, pp. 7169-77, 2009 (PubMed).

Mock, Krall, Kozak, Nesbitt, McBride, Renauld, Van Snick: "IL9 maps to mouse chromosome 13 and human chromosome 5." in: Immunogenetics, Vol. 31, Issue 4, pp. 265-70, 1990 (PubMed).